

Shuren Li

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1354387/publications.pdf>

Version: 2024-02-01

30
papers

905
citations

471509

17
h-index

501196

28
g-index

31
all docs

31
docs citations

31
times ranked

1058
citing authors

#	ARTICLE	IF	CITATIONS
1	State-of-the-art of nuclear medicine and molecular imaging in China: after the first 66 years (1956–2022). <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 2455-2461.	6.4	1
2	Comparison of 18f-FDOPA, 68Ga-DOTA-NOC and 18F-FDG PET for Imaging Pituitary Microadenoma. <i>World Journal of Nuclear Medicine</i> , 2022, , .	0.5	0
3	Antitumour effects of apatinib in progressive, metastatic differentiated thyroid cancer (DTC). <i>Endocrine</i> , 2022, 78, 68-76.	2.3	2
4	Evaluating the Long-Term Efficacy of Acupuncture Therapy for Subacute Poststroke Aphasia: Study Protocol for a Randomized, Blinded, Controlled, Multicentre Trial. <i>Evidence-based Complementary and Alternative Medicine</i> , 2021, 2021, 1-13.	1.2	2
5	Lesion Distribution and Early Changes of Right Hemisphere in Chinese Patients With Post-stroke Aphasia. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 632217.	3.4	1
6	Renal Cell Carcinoma: the Oncologist Asks, Can PSMA PET/CT Answer?. <i>Current Urology Reports</i> , 2019, 20, 68.	2.2	27
7	Acupuncture is effective in improving functional communication in post-stroke aphasia. <i>Wiener Klinische Wochenschrift</i> , 2019, 131, 221-232.	1.9	28
8	Total thyroidectomy (Tx) versus thionamides (antithyroid drugs) in patients with moderate-to-severe Graves' ophthalmopathy – a 1-year follow-up: study protocol for a randomized controlled trial. <i>Trials</i> , 2018, 19, 495.	1.6	2
9	The prognostic value of [123I]-vascular endothelial growth factor ([123I]-VEGF) in glioma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 2396-2403.	6.4	25
10	Calcium-stimulated calcitonin - The "new standard" in the diagnosis of thyroid C-cell disease - clinically relevant gender-specific cut-off levels for an "old test". <i>Biochemia Medica</i> , 2018, 28, 030710.	2.7	21
11	The value of [11C]-acetate PET and [18F]-FDG PET in hepatocellular carcinoma before and after treatment with transarterial chemoembolization and bevacizumab. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 1732-1741.	6.4	20
12	Effect of electroacupuncture in patients with post-stroke motor aphasia. <i>Wiener Klinische Wochenschrift</i> , 2017, 129, 102-109.	1.9	23
13	Hepatocellular Carcinoma: A Phase II Randomized Controlled Double-Blind Trial of Transarterial Chemoembolization in Combination with Biweekly Intravenous Administration of Bevacizumab or a Placebo. <i>Radiology</i> , 2015, 277, 903-912.	7.3	60
14	Acceptance of pelvic floor education as a treatment for female urinary incontinence by using biofeedback in a Viennese population of Turkish female migrants, Re: Keshwani N, McLean L. <i>State of the Art Review: Intravaginal probes for recording electromyogr. Neurourology and Urodynamics</i> , 2015, 34, 113-114.	1.5	2
15	Comparison of side effects of pentagastrin test and calcium stimulation test in patients with increased basal calcitonin concentration: the gender-specific differences. <i>Endocrine</i> , 2014, 46, 549-553.	2.3	16
16	Selenium intake and selenium blood levels: a novel food frequency questionnaire. <i>Wiener Klinische Wochenschrift</i> , 2013, 125, 160-164.	1.9	15
17	Vascular endothelial growth factor in thyroid cyst fluids. <i>Wiener Klinische Wochenschrift</i> , 2007, 119, 248-253.	1.9	5
18	Comparison of 11C-acetate positron emission tomography and 67Gallium citrate scintigraphy in patients with hepatocellular carcinoma. <i>Liver International</i> , 2006, 26, 920-927.	3.9	17

#	ARTICLE	IF	CITATIONS
19	Comparison of ¹¹¹ In-DOTA-DPhe ¹ -Tyr ³ -octreotide and ¹¹¹ In-DOTA- ¹ lanreotide scintigraphy and dosimetry in patients with neuroendocrine tumours. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2006, 33, 532-540.	6.4	49
20	^{99m} Tc-Depreotide Scintigraphy Versus ¹⁸ F-FDG-PET in the Diagnosis of Radioiodine-Negative Thyroid Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006, 91, 3997-4000.	3.6	24
21	¹¹ C-Acetate Positron Emission Tomography Imaging and Image Fusion With Computed Tomography and Magnetic Resonance Imaging in Patients With Recurrent Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2006, 24, 2513-2519.	1.6	114
22	The Radionuclide Molecular Imaging and Therapy of Neuroendocrine Tumors. <i>Current Cancer Drug Targets</i> , 2005, 5, 139-148.	1.6	30
23	Molecular imaging of atherosclerotic plaques with technetium- ^{99m} -labelled antisense oligonucleotides. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2005, 32, 6-14.	6.4	23
24	Value of ¹¹¹ In-DOTA- ¹ lanreotide and ¹¹¹ In-DOTA-DPhe ¹ -Tyr ³ -octreotide in differentiated thyroid cancer: results of in vitro binding studies and in vivo comparison with ¹⁸ F-FDG PET. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2005, 32, 1144-1151.	6.4	20
25	Effect of statins on lipoprotein receptor expression in cell lines from human mast cells and basophils. <i>European Journal of Clinical Pharmacology</i> , 2003, 59, 507-516.	1.9	9
26	¹¹¹ In-DOTA-dPhe ¹ -Tyr ³ -octreotide, ¹¹¹ In-DOTA- ¹ lanreotide and ⁶⁷ Ga citrate scintigraphy for visualisation of extranodal marginal zone B-cell lymphoma of the MALT type: a comparative study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2003, 30, 1087-1095.	6.4	13
27	Autocrine cell suicide in a Burkitt lymphoma cell line (Daudi) induced by interferon γ : involvement of tumor necrosis factor as ligand for the CD95 receptor. <i>Blood</i> , 2001, 97, 2791-2797.	1.4	16
28	Characterization of ¹²³ I-vascular endothelial growth factor-binding sites expressed on human tumour cells: Possible implication for tumour scintigraphy. <i>International Journal of Cancer</i> , 2001, 91, 789-796.	5.1	66
29	In vitro and in vivo studies of three radiolabelled somatostatin analogues: ¹²³ I-Octreotide (OCT), ¹²³ I-Tyr ³ -OCT and ¹¹¹ In-TIRA-d-Phe ¹ -OCT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1996, 23, 1388-1399.	2.1	31
30	Vasoactive Intestinal Peptide-Receptor Imaging for the Localization of Intestinal Adenocarcinomas and Endocrine Tumors. <i>New England Journal of Medicine</i> , 1994, 331, 1116-1121.	27.0	243